• Read more about July Social Media Round-Up—Rocky Mount Update, Rady Johnson Honored, and Vaccine Progress

On July 20, a tornado touched down in North Carolina, injuring 16 people and damaging a Pfizer plant in Rocky Mount, one of the largest manufacturers of sterile injectable drugs in the world. This month’s social media round-up kicks off with a statement from CEO Albert Bourla about the tornado and its impact on Pfizer.

• Read more about Pfizer Receives Positive CHMP Opinion for Alopecia Areata Treatment

New York, July 21, 2023 — Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for LITFULO™ (ritlecitinib), an oral treatment, recommending marketing authorization of once-daily 50 mg for individuals 12 years of age and older with severe alopecia areata.

• Read more about Pfizer Receives Positive CHMP Opinion for RSV Vaccine Candidate to Help Protect Infants through Maternal Immunization and Older Adults

•    Pfizer’s RSV vaccine candidate, RSVpreF, would help address substantial burden of RSV disease in individuals 60 years of age and older and in infants from birth through six months of age
•    If approved, Pfizer’s RSV vaccine candidate would be first and only vaccine for both older adults and administration to pregnant individuals to help protect their infants 

• Read more about Pfizer’s Social Media Round-Up—June Edition

As a Fortune 50 company at the forefront of healthcare and science, Pfizer leadership consistently leads the conversation, drives discussion, and impacts markets.  It can be tough to keep up with the constant flow of content as the company, our executives, and our initiatives make news online, in the business world, and in our lives. 

• Read more about Pfizer Joins Annual Brunch Run to Support Cancer Support Non-Profit Imerman Angels

• Read more about Pfizer and the European Commission Enter into Manufacturing Reservation Agreement for mRNA-based Vaccines to Help Protect Against Future Pandemics

NEW YORK, June 30, 2023 — Pfizer Inc. (NYSE: PFE) announced today that it has entered into a manufacturing capacity reservation agreement with the European Health and Digital Executive Agency (HaDEA) of the European Commission (EC), which provides the European Union (EU) access to doses of a mRNA-based vaccine should one be developed to protect against a future pandemic-causing disease.

• Read more about Pfizer and BioNTech Submit Applications to U.S. FDA for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine

• The submissions reflect guidance from FDA and other major health authorities to provide COVID-19 vaccines better matched to currently circulating sublineages
• The companies expect to be ready to ship the adapted vaccines immediately following regulatory authorization/approval

NEW YORK and MAINZ, GERMANY, JUNE 23, 2023 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the companies have submitted regulatory applications to the U.S.

• Read more about Pfizer and BioNTech Initiate Application to European Medicines Agency for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine

• The application reflects guidance from EMA and other major health authorities to provide COVID-19 vaccines better matched to currently circulating sublineages
• The companies expect to be ready to ship the adapted vaccines to EU member states immediately following regulatory approval  
• Application in the U.S. expected to follow in the coming days

NEW YORK and MAINZ, GERMANY, JUNE 23, 2023 — Pfizer Inc.

• Read more about Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-valent Pneumococcal Conjugate Vaccine) in Infants and Children

NEW YORK, N.Y., June 22, 2023 - Pfizer Inc. (NYSE: PFE) announced today that the U.S.

• Read more about Pfizer’s ABRYSVO™ Receives Recommendation for Use in Older Adults from Advisory Committee on Immunization Practices

• ABRYSVO recommended for adults 60 years and older to help protect against Respiratory Syncytial Virus (RSV) disease 
• Pfizer presented initial data from mid- RSV season two in the Northern Hemisphere, which demonstrated ABRYSVO maintained efficacy against RSV-associated lower respiratory tract disease (LRTD)
• Additional data presented by Pfizer supports coadministration of ABRYSVO with flu vaccine in older adults 

NEW YORK, June 22, 2023 – Pfizer Inc. (NYSE: PFE) announced today that the U.S.